O Shaughnessy Asset Management LLC Grows Holdings in ImmunoGen, Inc. (NASDAQ:IMGN)

O Shaughnessy Asset Management LLC raised its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN) by 13.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,052 shares of the biotechnology company’s stock after buying an additional 1,893 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in ImmunoGen were worth $106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently made changes to their positions in IMGN. Marshall Wace North America L.P. purchased a new position in shares of ImmunoGen in the first quarter valued at $52,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of ImmunoGen by 72.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 31,633 shares of the biotechnology company’s stock valued at $256,000 after buying an additional 13,307 shares during the period. Commonwealth Equity Services LLC increased its stake in shares of ImmunoGen by 74.5% during the first quarter. Commonwealth Equity Services LLC now owns 44,086 shares of the biotechnology company’s stock valued at $357,000 after buying an additional 18,828 shares during the period. Envestnet Asset Management Inc. grew its stake in ImmunoGen by 8.2% in the first quarter. Envestnet Asset Management Inc. now owns 60,308 shares of the biotechnology company’s stock valued at $488,000 after purchasing an additional 4,583 shares during the last quarter. Finally, Blueshift Asset Management LLC purchased a new position in ImmunoGen in the first quarter valued at about $216,000. 89.18% of the stock is owned by institutional investors and hedge funds.

Shares of IMGN stock opened at $5.93 on Wednesday. ImmunoGen, Inc. has a fifty-two week low of $3.43 and a fifty-two week high of $10.88. The firm has a market capitalization of $1.20 billion, a price-to-earnings ratio of -20.45 and a beta of 1.33. The stock’s 50-day simple moving average is $5.69 and its 200-day simple moving average is $6.68.

ImmunoGen (NASDAQ:IMGN) last released its earnings results on Friday, July 30th. The biotechnology company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.03. ImmunoGen had a negative return on equity of 106.62% and a negative net margin of 40.82%. The firm had revenue of $16.90 million during the quarter, compared to the consensus estimate of $18.92 million. The company’s revenue for the quarter was up 12.7% compared to the same quarter last year. As a group, equities analysts expect that ImmunoGen, Inc. will post -0.73 earnings per share for the current year.

ImmunoGen Company Profile

ImmunoGen, Inc engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Featured Article: Trade War

Institutional Ownership by Quarter for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.